The Weekly Roundup: June 10-14

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Safety vs Efficacy: What AD Treatments Can Be Used in Pediatric Patients?

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

FDA Approves Expanded Use of Tirbanibulin for Actinic Keratosis

Phase 3 clinical trial results showed that the safety and tolerability profiles were consistent with those observed in the original pivotal trials.

Comparing AD Guidelines From Around the World

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Promising Results in Phase 2 Trial of ProSilic

The trial reported complete hair regrowth for a number of participants, with 76% of a partial cohort meeting the primary endpoint of 30% improvement.

Exploring New Pathways in Atopic Dermatitis

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Looking Ahead to Advancements in Vitiligo and Atopic Dermatitis

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

MoonLake Immunotherapeutics Announces FDA, EMA Support of Furthering Phase 3 Sonelokimab for PsA

The phase 3 IZAR program will evaluate the efficacy and safety of sonelokimab in patients with psoriatic arthritis for a 1 year duration.

Addressing Itch and Remission in Atopic Dermatitis

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

Late-Breaker: Roflumilast Cream 0.15% Demonstrates Continued Improvement in AD Symptoms Through 56 Weeks

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Late-Breaker: Upadacitinib Demonstrates Superiority Over Dupilumab in All Ranked Secondary End Points of Head-to-Head AD Study

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Day 2 Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Disease Severity and Age Can Affect Impact of AD

A study out of Japan found the burden on patients with atopic dermatitis and their caregivers can increase with age and disease severity.

The Road to Relief: Navigating a Personal Atopic Dermatitis Journey

Kristine Kucera, PA-C, MPAS, DHS, discusses the atopic dermatitis patient experience alongside one of her patients, Mickey Bryson.

“Apply to Affected Area BID x 2 Weeks Then PRN”

Step therapy can delay appropriate care and potentially worsen patients' conditions, writes Dermatology Times' Spring Editor in Chief, Aaron Farberg, MD.

Prioritizing Itch and Sleep Improvement in Atopic Dermatitis

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Can AI Diagnose Dermatological Conditions?

A recent study investigated the technology as a resource for patients seeking online medical information.

Late-Breaker: Positive 52-week Data for Rademikibart in Patients with AD

The data, presented at RAVE 2024, continued a positive trend, building upon strong phase 1 results of rademikibart for patients with AD.

Battle of the Two Titans: When to Progress AD Patients to Systemic Therapy

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC, debated which patients are a contender for systemic therapy.

Conference Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema

Catch up on all clinical pearls from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

FROM THE COVER: E-Cigarettes and Vaping - Clinical Implications of Dermapathology, Impact on Atopic Dermatitis

Researchers hypothesize that skin contact with e-cigarette fluids can trigger an inflammatory response.

Study Investigates Ties Between Vitiligo and Parkinson’s Disease

The study found patients with vitiligo are at a lower risk of developing PD, but those with comorbid PD could face elevated mortality rates.

Review: Serum Concentrations of Vitamin D, Vitamin E, and Zinc Lower in Patients With Vitiligo

Conversely, there were higher levels of selenium and folic acid detected in patients with vitiligo versus otherwise healthy individuals.

What Conferences Are You Planning to Attend in Quarter 3 of 2024?

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between July and September. Share your thoughts with us by June 26.

Can Teledermatology Support Patient Care?

A recent review found that teledermatology could improve patient access, increase efficiency, and cut down on costly hospital admissions.

An Increase in Skin Cancer Calls for an Increase in Treatment Options

To address the increased rates of skin cancer while keeping unique patient needs top of mind, there is a pressing need to increase options for treatment.

Alice Gottlieb, MD, PhD: Preventing Pain and Disability in Psoriatic Disease

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

FDA Approves Tralokinumab Autoinjector for Adults With Moderate to Severe Atopic Dermatitis

LEO Pharma's Adbry, a single-dose autoinjector, is expected to become available to patients in the coming months.

Providing Patients With Multidisciplinary, Preventative Care in the Management of Albinism

Today, June 13, is the 10th annual International Albinism Awareness Day.

First Patients Dosed with VYN202 for Inflammatory Diseases

VYNE Therapeutics Inc. shared that top-line data from the trial is expected in the second half of 2024.

Fostering Mentorship and Support in Early-Stage Physician Assistants

Aubrie Jones, PA-C, MMS, and Laura Bush, DMSc, PA-C, DFAAPA, discuss the role of the SDPA in supporting the growth and journeys of PAs at all stages.

Analyzing the Impact of AD on Women’s Sexual Health

A recent study found that AD not only affects mental health and QoL, but women’s sexual health and gestational desires as well.

Top 5 Pearls and Expert Insights From the 2024 SDPA Summer Conference

Review our coverage and expert interviews from the recent Society of Dermatology Physician Assistants' annual summer meeting.

Top 5 Strategies to Switch From Practice to Pharma

Terry Arnold, PA-C, shares a wide range of opportunities to take clinical experience to a different setting and tips to transition.

New, Difficult-to-Treat Fungal Skin Infections Are Emerging, Clinicians Warn

Two new forms of Trichophyton mentagrophytes type VII and Trichophyton indotineae are emerging, according to a new report.

Hormonal and Mental Health Implications of Acne: Selecting Appropriate Treatments for Patients

Although acne is common for most people to experience in their lifetime, it is important to individualize treatment and provide appropriate care when working with a diverse patient base.

Rapid Growth in Dermatology PAs: New Certification Exam Shows Reasonable Alignment with US Skin Disease Burden, Potential for Refinement

Researchers compared the examination's content outline with data on skin diseases in a recent study.

ILDS, Patient Associations Call for Prioritization of Skin Diseases on a Global Scale

The organizations called for skin health to be considered a global public health priority in a recent side meeting at the World Health Assembly.

Skin Cancer Fellowship Celebrates 40th Graduating Class

The program’s creator, Hubert Greenway, MD, has personally trained each of the fellowship’s 68 physicians in Mohs surgery.